Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists.
Eplerenone
Finerenone
Mineralocorticoid receptor
Mineralocorticoid receptor antagonists
Review
Spironolactone
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
21 Dec 2023
21 Dec 2023
Historique:
received:
24
07
2023
accepted:
13
09
2023
medline:
21
12
2023
pubmed:
21
12
2023
entrez:
21
12
2023
Statut:
aheadofprint
Résumé
The overactivation of the mineralocorticoid receptor (MR) promotes pathophysiological processes related to multiple physiological systems, including the heart, vasculature, adipose tissue and kidneys. The inhibition of the MR with classical MR antagonists (MRA) has successfully improved outcomes most evidently in heart failure. However, real and perceived risk of side effects and limited tolerability associated with classical MRA have represented barriers to implementing MRA in settings where they have been already proven efficacious (heart failure with reduced ejection fraction) and studying their potential role in settings where they might be beneficial but where risk of safety events is perceived to be higher (renal disease). Novel non-steroidal MRA have distinct properties that might translate into favourable clinical effects and better safety profiles as compared with MRA currently used in clinical practice. Randomised trials have shown benefits of non-steroidal MRA in a range of clinical contexts, including diabetic kidney disease, hypertension and heart failure. This review provides an overview of the literature on the systemic impact of MR overactivation across organ systems. Moreover, we summarise the evidence from preclinical studies and clinical trials that have set the stage for a potential new paradigm of MR antagonism.
Identifiants
pubmed: 38127122
doi: 10.1007/s00125-023-06031-1
pii: 10.1007/s00125-023-06031-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Shibata S, Nagase M, Yoshida S et al (2008) Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 14(12):1370–1376. https://doi.org/10.1038/nm.1879
doi: 10.1038/nm.1879
pubmed: 19029984
Ingelsson E, Pencina MJ, Tofler GH et al (2007) Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 116(9):984–992. https://doi.org/10.1161/CIRCULATIONAHA.107.708537
doi: 10.1161/CIRCULATIONAHA.107.708537
pubmed: 17698726
Beygui F, Collet JP, Benoliel JJ et al (2006) High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 114(24):2604–2610. https://doi.org/10.1161/CIRCULATIONAHA.106.634626
doi: 10.1161/CIRCULATIONAHA.106.634626
pubmed: 17116769
Güder G, Bauersachs J, Frantz S et al (2007) Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115(13):1754–1761. https://doi.org/10.1161/CIRCULATIONAHA.106.653964
doi: 10.1161/CIRCULATIONAHA.106.653964
pubmed: 17372171
Agarwal R, Kolkhof P, Bakris G et al (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42(2):152–161. https://doi.org/10.1093/eurheartj/ehaa736
doi: 10.1093/eurheartj/ehaa736
pubmed: 33099609
Williams B, MacDonald TM, Morant S et al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386(10008):2059–2068. https://doi.org/10.1016/S0140-6736(15)00257-3
doi: 10.1016/S0140-6736(15)00257-3
pubmed: 26414968
pmcid: 4655321
McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368
doi: 10.1093/eurheartj/ehab368
pubmed: 34447992
Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21. https://doi.org/10.1056/NEJMoa1009492
doi: 10.1056/NEJMoa1009492
pubmed: 21073363
Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–717. https://doi.org/10.1056/nejm199909023411001
doi: 10.1056/nejm199909023411001
pubmed: 10471456
Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309–1321. https://doi.org/10.1056/NEJMoa030207
doi: 10.1056/NEJMoa030207
pubmed: 12668699
Solomon SD, Claggett B, Lewis EF et al (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37(5):455–462. https://doi.org/10.1093/eurheartj/ehv464
doi: 10.1093/eurheartj/ehv464
pubmed: 26374849
Greene SJ, Tan X, Yeh YC et al (2021) Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. Heart Fail Rev. https://doi.org/10.1007/s10741-021-10077-x
doi: 10.1007/s10741-021-10077-x
pubmed: 33913077
Savarese G, Carrero JJ, Pitt B et al (2018) Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 20(9):1326–1334. https://doi.org/10.1002/ejhf.1182
doi: 10.1002/ejhf.1182
pubmed: 29578280
Greene SJ, Butler J, Albert NM et al (2018) Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 72(4):351–366. https://doi.org/10.1016/j.jacc.2018.04.070
doi: 10.1016/j.jacc.2018.04.070
pubmed: 30025570
Group KDIGOKDW (2022) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 102(5S):S1–S127. https://doi.org/10.1016/j.kint.2022.06.008
doi: 10.1016/j.kint.2022.06.008
Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219–2229. https://doi.org/10.1056/NEJMoa2025845
doi: 10.1056/NEJMoa2025845
pubmed: 33264825
Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252–2263. https://doi.org/10.1056/NEJMoa2110956
doi: 10.1056/NEJMoa2110956
pubmed: 34449181
Agarwal R, Filippatos G, Pitt B et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474–484. https://doi.org/10.1093/eurheartj/ehab777
doi: 10.1093/eurheartj/ehab777
pubmed: 35023547
Simpson SA, Tait JF, Wettstein A, Neher R, Von Euw J, Reichstein T (1953) Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism. Experientia 9(9):333–335. https://doi.org/10.1007/BF02155834
doi: 10.1007/BF02155834
pubmed: 13107656
August JT, Nelson DH, Thorn GW (1958) Aldosterone. N Engl J Med 259(19):917–923. https://doi.org/10.1056/NEJM195811062591907
doi: 10.1056/NEJM195811062591907
pubmed: 13600594
Sala G, Luetscher JA (1954) The effect of sodium-retaining corticoid, electrocortin, desoxycorticosterone, and cortisone on renal function and excretion of sodium and water in adrenalectomized rats. Endocrinology 55(4):516–518. https://doi.org/10.1210/endo-55-4-516
doi: 10.1210/endo-55-4-516
pubmed: 13200463
Feldman D, Funder JW, Edelman IS (1972) Subcellular mechanisms in the action of adrenal steroids. Am J Med 53(5):545–560. https://doi.org/10.1016/0002-9343(72)90152-0
doi: 10.1016/0002-9343(72)90152-0
pubmed: 5079762
Corvol P, Claire M, Oblin ME, Geering K, Rossier B (1981) Mechanism of the antimineralocorticoid effects of spirolactones. Kidney Int 20(1):1–6. https://doi.org/10.1038/ki.1981.97
doi: 10.1038/ki.1981.97
pubmed: 7029118
Kolkhof P, Bärfacker L (2017) 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol 234(1):T125–T140. https://doi.org/10.1530/JOE-16-0600
doi: 10.1530/JOE-16-0600
pubmed: 28634268
pmcid: 5488394
Arriza JL, Weinberger C, Cerelli G et al (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237(4812):268–275. https://doi.org/10.1126/science.3037703
doi: 10.1126/science.3037703
pubmed: 3037703
Gomez-Sanchez E, Gomez-Sanchez CE (2014) The multifaceted mineralocorticoid receptor. Compr Physiol 4(3):965–994. https://doi.org/10.1002/cphy.c130044
doi: 10.1002/cphy.c130044
pubmed: 24944027
pmcid: 4521600
Pandey AK, Bhatt DL, Cosentino F et al (2022) Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Eur Heart J 43(31):2931–2945. https://doi.org/10.1093/eurheartj/ehac299
doi: 10.1093/eurheartj/ehac299
pubmed: 35713973
Brown NJ (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9(8):459–469. https://doi.org/10.1038/nrneph.2013.110
doi: 10.1038/nrneph.2013.110
pubmed: 23774812
pmcid: 3922409
Agarwal MK, Mirshahi M (1999) General overview of mineralocorticoid hormone action. Pharmacol Ther 84(3):273–326. https://doi.org/10.1016/s0163-7258(99)00038-8
doi: 10.1016/s0163-7258(99)00038-8
pubmed: 10665831
Fuller PJ, Yang J, Young MJ (2019) Mechanisms of mineralocorticoid receptor signaling. Vitam Horm 109:37–68. https://doi.org/10.1016/bs.vh.2018.09.004
doi: 10.1016/bs.vh.2018.09.004
pubmed: 30678864
Gomez-Sanchez CE, Gomez-Sanchez EP (2021) The mineralocorticoid receptor and the heart. Endocrinology 162(11). https://doi.org/10.1210/endocr/bqab131
Wendler A, Baldi E, Harvey BJ, Nadal A, Norman A, Wehling M (2010) Position paper: rapid responses to steroids: current status and future prospects. Eur J Endocrinol 162(5):825–830. https://doi.org/10.1530/EJE-09-1072
doi: 10.1530/EJE-09-1072
pubmed: 20194525
Feldman RD, Gros R (2011) Unraveling the mechanisms underlying the rapid vascular effects of steroids: sorting out the receptors and the pathways. Br J Pharmacol 163(6):1163–1169. https://doi.org/10.1111/j.1476-5381.2011.01366.x
doi: 10.1111/j.1476-5381.2011.01366.x
pubmed: 21545416
pmcid: 3144532
Grossmann C, Benesic A, Krug AW et al (2005) Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol 19(7):1697–1710. https://doi.org/10.1210/me.2004-0469
doi: 10.1210/me.2004-0469
pubmed: 15761031
Briet M, Schiffrin EL (2010) Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 6(5):261–273. https://doi.org/10.1038/nrneph.2010.30
doi: 10.1038/nrneph.2010.30
pubmed: 20234356
Funder JW, Pearce PT, Smith R, Campbell J (1989) Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 125(4):2224–2226. https://doi.org/10.1210/endo-125-4-2224
doi: 10.1210/endo-125-4-2224
pubmed: 2551643
Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T (2007) Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49(2):355–364. https://doi.org/10.1161/01.HYP.0000255636.11931.a2
doi: 10.1161/01.HYP.0000255636.11931.a2
pubmed: 17200434
Lother A, Moser M, Bode C, Feldman RD, Hein L (2015) Mineralocorticoids in the heart and vasculature: new insights for old hormones. Annu Rev Pharmacol Toxicol 55:289–312. https://doi.org/10.1146/annurev-pharmtox-010814-124302
doi: 10.1146/annurev-pharmtox-010814-124302
pubmed: 25251996
Fraccarollo D, Berger S, Galuppo P et al (2011) Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123(4):400–408. https://doi.org/10.1161/CIRCULATIONAHA.110.983023
doi: 10.1161/CIRCULATIONAHA.110.983023
pubmed: 21242479
Lother A, Berger S, Gilsbach R et al (2011) Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57(4):746–754. https://doi.org/10.1161/HYPERTENSIONAHA.110.163287
doi: 10.1161/HYPERTENSIONAHA.110.163287
pubmed: 21321305
Caprio M, Newfell BG, la Sala A et al (2008) Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102(11):1359–1367. https://doi.org/10.1161/CIRCRESAHA.108.174235
doi: 10.1161/CIRCRESAHA.108.174235
pubmed: 18467630
pmcid: 2597516
Lombès M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP (1992) Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 71(3):503–510. https://doi.org/10.1161/01.res.71.3.503
doi: 10.1161/01.res.71.3.503
pubmed: 1323429
Urbanet R, Nguyen Dinh Cat A, Feraco A et al (2015) Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase. Hypertension 66(1):149–157. https://doi.org/10.1161/HYPERTENSIONAHA.114.04981
doi: 10.1161/HYPERTENSIONAHA.114.04981
pubmed: 25966493
Marzolla V, Armani A, Feraco A et al (2014) Mineralocorticoid receptor in adipocytes and macrophages: a promising target to fight metabolic syndrome. Steroids 91:46–53. https://doi.org/10.1016/j.steroids.2014.05.001
doi: 10.1016/j.steroids.2014.05.001
pubmed: 24819992
Gass P, Kretz O, Wolfer DP et al (2000) Genetic disruption of mineralocorticoid receptor leads to impaired neurogenesis and granule cell degeneration in the hippocampus of adult mice. EMBO Rep 1(5):447–451. https://doi.org/10.1093/embo-reports/kvd088
doi: 10.1093/embo-reports/kvd088
pubmed: 11258486
pmcid: 1083761
Odermatt A, Kratschmar DV (2012) Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: an overview. Mol Cell Endocrinol 350(2):168–186. https://doi.org/10.1016/j.mce.2011.07.020
doi: 10.1016/j.mce.2011.07.020
pubmed: 21820034
Rossier BC, Baker ME, Studer RA (2015) Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited. Physiol Rev 95(1):297–340. https://doi.org/10.1152/physrev.00011.2014
doi: 10.1152/physrev.00011.2014
pubmed: 25540145
Gomez-Sanchez EP, Gomez-Sanchez CE (2021) 11β-Hydroxysteroid dehydrogenases: a growing multi-tasking family. Mol Cell Endocrinol 526:111210. https://doi.org/10.1016/j.mce.2021.111210
doi: 10.1016/j.mce.2021.111210
pubmed: 33607268
pmcid: 8108011
Tesch GH, Young MJ (2017) Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis. Front Pharmacol 8:313. https://doi.org/10.3389/fphar.2017.00313
doi: 10.3389/fphar.2017.00313
pubmed: 28611666
pmcid: 5447060
Schwenk MH, Hirsch JS, Bomback AS (2015) Aldosterone blockade in CKD: emphasis on pharmacology. Adv Chronic Kidney Dis 22(2):123–132. https://doi.org/10.1053/j.ackd.2014.08.003
doi: 10.1053/j.ackd.2014.08.003
pubmed: 25704349
Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG (2003) Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63(5):1791–1800. https://doi.org/10.1046/j.1523-1755.2003.00929.x
doi: 10.1046/j.1523-1755.2003.00929.x
pubmed: 12675855
Greene EL, Kren S, Hostetter TH (1996) Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98(4):1063–1068. https://doi.org/10.1172/JCI118867
doi: 10.1172/JCI118867
pubmed: 8770880
pmcid: 507523
Selye H (1958) Experimental production of endomyocardial fibrosis. Lancet 1(7035):1351–1353. https://doi.org/10.1016/s0140-6736(58)92163-9
doi: 10.1016/s0140-6736(58)92163-9
pubmed: 13551003
Brilla CG, Weber KT (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120(6):893–901
pubmed: 1453111
Brilla CG, Matsubara LS, Weber KT (1993) Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25(5):563–575. https://doi.org/10.1006/jmcc.1993.1066
doi: 10.1006/jmcc.1993.1066
pubmed: 8377216
Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ (2009) Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54(3):537–543. https://doi.org/10.1161/HYPERTENSIONAHA.109.131110
doi: 10.1161/HYPERTENSIONAHA.109.131110
pubmed: 19635989
Wang YL, Ma XX, Li RG et al (2023) T-cell mineralocorticoid receptor deficiency attenuates pathologic ventricular remodelling after myocardial infarction. Can J Cardiol 39(5):593–604. https://doi.org/10.1016/j.cjca.2023.01.013
doi: 10.1016/j.cjca.2023.01.013
pubmed: 36669686
Hirata A, Maeda N, Hiuge A et al (2009) Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 84(1):164–172. https://doi.org/10.1093/cvr/cvp191
doi: 10.1093/cvr/cvp191
pubmed: 19505930
Guo C, Ricchiuti V, Lian BQ et al (2008) Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 117(17):2253–2261. https://doi.org/10.1161/CIRCULATIONAHA.107.748640
doi: 10.1161/CIRCULATIONAHA.107.748640
pubmed: 18427128
pmcid: 2746647
Luther JM, Luo P, Kreger MT et al (2011) Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 54(8):2152–2163. https://doi.org/10.1007/s00125-011-2158-9
doi: 10.1007/s00125-011-2158-9
pubmed: 21519965
pmcid: 3216479
Luo P, Dematteo A, Wang Z et al (2013) Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice. Diabetologia 56(4):901–910. https://doi.org/10.1007/s00125-012-2814-8
doi: 10.1007/s00125-012-2814-8
pubmed: 23314847
pmcid: 3593801
Briones AM, Nguyen Dinh Cat A, Callera GE et al (2012) Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59(5):1069–1078. https://doi.org/10.1161/HYPERTENSIONAHA.111.190223
doi: 10.1161/HYPERTENSIONAHA.111.190223
pubmed: 22493070
Bruder-Nascimento T, da Silva MA, Tostes RC (2014) The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes. Diabetol Metab Syndr 6(1):90. https://doi.org/10.1186/1758-5996-6-90
doi: 10.1186/1758-5996-6-90
pubmed: 25352918
pmcid: 4210491
Catena C, Lapenna R, Baroselli S et al (2006) Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91(9):3457–3463. https://doi.org/10.1210/jc.2006-0736
doi: 10.1210/jc.2006-0736
pubmed: 16822818
Monticone S, D’Ascenzo F, Moretti C et al (2018) Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 6(1):41–50. https://doi.org/10.1016/S2213-8587(17)30319-4
doi: 10.1016/S2213-8587(17)30319-4
pubmed: 29129575
Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA (2007) Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30(9):2349–2354. https://doi.org/10.2337/dc07-0525
doi: 10.2337/dc07-0525
pubmed: 17575088
Hosoya K, Minakuchi H, Wakino S et al (2015) Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans. Kidney Int 87(4):749–760. https://doi.org/10.1038/ki.2014.348
doi: 10.1038/ki.2014.348
pubmed: 25337775
Freel EM, Tsorlalis IK, Lewsey JD et al (2009) Aldosterone status associated with insulin resistance in patients with heart failure–data from the ALOFT study. Heart 95(23):1920–1924. https://doi.org/10.1136/hrt.2009.173344
doi: 10.1136/hrt.2009.173344
pubmed: 19713201
Felder RB, Yu Y, Zhang ZH, Wei SG (2009) Pharmacological treatment for heart failure: a view from the brain. Clin Pharmacol Ther 86(2):216–220. https://doi.org/10.1038/clpt.2009.117
doi: 10.1038/clpt.2009.117
pubmed: 19553933
Koenig JB, Jaffe IZ (2014) Direct role for smooth muscle cell mineralocorticoid receptors in vascular remodeling: novel mechanisms and clinical implications. Curr Hypertens Rep 16(5):427. https://doi.org/10.1007/s11906-014-0427-y
doi: 10.1007/s11906-014-0427-y
pubmed: 24633842
pmcid: 4026046
Bioletto F, Bollati M, Lopez C et al (2022) Primary aldosteronism and resistant hypertension: a pathophysiological insight. Int J Mol Sci 23(9):4803. https://doi.org/10.3390/ijms23094803
doi: 10.3390/ijms23094803
pubmed: 35563192
pmcid: 9100181
Harvey AP, Montezano AC, Hood KY et al (2017) Vascular dysfunction and fibrosis in stroke-prone spontaneously hypertensive rats: the aldosterone-mineralocorticoid receptor-Nox1 axis. Life Sci 179:110–119. https://doi.org/10.1016/j.lfs.2017.05.002
doi: 10.1016/j.lfs.2017.05.002
pubmed: 28478264
pmcid: 5446265
Rossier MF (2021) The cardiac mineralocorticoid receptor (MR): a therapeutic target against ventricular arrhythmias. Front Endocrinol (Lausanne) 12:694758. https://doi.org/10.3389/fendo.2021.694758
doi: 10.3389/fendo.2021.694758
pubmed: 34262530
Hené RJ, Boer P, Koomans HA, Mees EJ (1982) Plasma aldosterone concentrations in chronic renal disease. Kidney Int 21(1):98–101. https://doi.org/10.1038/ki.1982.14
doi: 10.1038/ki.1982.14
pubmed: 7043053
McKelvie RS, Yusuf S, Pericak D et al (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100(10):1056–1064. https://doi.org/10.1161/01.cir.100.10.1056
doi: 10.1161/01.cir.100.10.1056
pubmed: 10477530
Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH (2004) Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47(11):1936–1939. https://doi.org/10.1007/s00125-004-1542-0
doi: 10.1007/s00125-004-1542-0
pubmed: 15551047
Cicoira M, Zanolla L, Rossi A et al (2001) Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 37(7):1808–1812. https://doi.org/10.1016/s0735-1097(01)01237-2
doi: 10.1016/s0735-1097(01)01237-2
pubmed: 11401115
MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD (1999) How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82(1):57–61. https://doi.org/10.1136/hrt.82.1.57
doi: 10.1136/hrt.82.1.57
pubmed: 10377310
pmcid: 1729098
Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB (2012) Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. J Am Soc Hypertens 6(5):338–345. https://doi.org/10.1016/j.jash.2012.07.003
doi: 10.1016/j.jash.2012.07.003
pubmed: 22995802
Bomback AS, Klemmer PJ (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3(9):486–492. https://doi.org/10.1038/ncpneph0575
doi: 10.1038/ncpneph0575
pubmed: 17717561
Bochud M, Nussberger J, Bovet P et al (2006) Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48(2):239–245. https://doi.org/10.1161/01.HYP.0000231338.41548.fc
doi: 10.1161/01.HYP.0000231338.41548.fc
pubmed: 16785327
Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M (1981) The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304(16):930–933. https://doi.org/10.1056/NEJM198104163041602
doi: 10.1056/NEJM198104163041602
pubmed: 7010165
Kagawa CM, Cella JA, Van Arman CG (1957) Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science 126(3281):1015–1016. https://doi.org/10.1126/science.126.3281.1015
doi: 10.1126/science.126.3281.1015
pubmed: 13486053
Liddle GW (1957) Sodium diuresis induced by steroidal antagonists of aldosterone. Science 126(3281):1016–1018. https://doi.org/10.1126/science.126.3281.1016
doi: 10.1126/science.126.3281.1016
pubmed: 13486054
Garthwaite SM, McMahon EG (2004) The evolution of aldosterone antagonists. Mol Cell Endocrinol 217(1–2):27–31. https://doi.org/10.1016/j.mce.2003.10.005
doi: 10.1016/j.mce.2003.10.005
pubmed: 15134797
Edelmann F, Wachter R, Schmidt AG et al (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309(8):781–791. https://doi.org/10.1001/jama.2013.905
doi: 10.1001/jama.2013.905
pubmed: 23443441
Pitt B, Pfeffer MA, Assmann SF et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383–1392. https://doi.org/10.1056/NEJMoa1313731
doi: 10.1056/NEJMoa1313731
pubmed: 24716680
Rossignol P, Zannad F (2015) Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west. Circulation 131(1):7–10. https://doi.org/10.1161/CIRCULATIONAHA.114.013637
doi: 10.1161/CIRCULATIONAHA.114.013637
pubmed: 25406307
ClinicalTrials.gov (2023) Spironolactone in the treatment of heart failure. Available from https://clinicaltrials.gov/ct2/show/NCT04727073 . Accessed 21 July 2023
ClinicalTrials.gov (2023) Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction. Available from https://clinicaltrials.gov/ct2/show/NCT02901184 . Accessed 21 July 2023
Sica DA (2005) Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10(1):23–29. https://doi.org/10.1007/s10741-005-2345-1
doi: 10.1007/s10741-005-2345-1
pubmed: 15947888
Clark E (1965) Spironolactone therapy and gynecomastia. JAMA 193:163–164. https://doi.org/10.1001/jama.1965.03090020077026
doi: 10.1001/jama.1965.03090020077026
pubmed: 14304369
Seferovic PM, Pelliccia F, Zivkovic I et al (2015) Mineralocorticoid receptor antagonists, a class beyond spironolactone–focus on the special pharmacologic properties of eplerenone. Int J Cardiol 200:3–7. https://doi.org/10.1016/j.ijcard.2015.02.096
doi: 10.1016/j.ijcard.2015.02.096
pubmed: 26404746
Vukadinović D, Lavall D, Vukadinović AN, Pitt B, Wagenpfeil S, Böhm M (2017) True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis. Am Heart J 188:99–108. https://doi.org/10.1016/j.ahj.2017.03.011
doi: 10.1016/j.ahj.2017.03.011
pubmed: 28577687
Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351(6):543–551. https://doi.org/10.1056/NEJMoa040135
doi: 10.1056/NEJMoa040135
pubmed: 15295047
Ferreira JP, Mogensen UM, Jhund PS et al (2020) Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail 22(11):2056–2064. https://doi.org/10.1002/ejhf.1987
doi: 10.1002/ejhf.1987
pubmed: 32809261
Savarese G, Xu H, Trevisan M et al (2019) Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 7(1):65–76. https://doi.org/10.1016/j.jchf.2018.10.003
doi: 10.1016/j.jchf.2018.10.003
pubmed: 30553905
Cooper LB, Benson L, Mentz RJ et al (2020) Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. Eur J Heart Fail 22(8):1390–1398. https://doi.org/10.1002/ejhf.1757
doi: 10.1002/ejhf.1757
pubmed: 32078214
Trevisan M, Fu EL, Xu Y et al (2021) Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail 23(10):1698–1707. https://doi.org/10.1002/ejhf.2287
doi: 10.1002/ejhf.2287
pubmed: 34196082
Butler J, Anker SD, Lund LH et al (2022) Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 43(41):4362–4373. https://doi.org/10.1093/eurheartj/ehac401
doi: 10.1093/eurheartj/ehac401
pubmed: 35900838
pmcid: 9622299
Janse RJ, Fu EL, Dahlström U et al (2022) Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician’s prescriptions to patient’s dispensations, medication adherence and persistence. Eur J Heart Fail 24(11):2185–2195. https://doi.org/10.1002/ejhf.2620
doi: 10.1002/ejhf.2620
pubmed: 35851740
Vaduganathan M, Ferreira JP, Rossignol P et al (2022) Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure. Eur J Heart Fail 24(9):1586–1590. https://doi.org/10.1002/ejhf.2635
doi: 10.1002/ejhf.2635
pubmed: 35867859
Savarese G, Kishi T, Vardeny O et al (2023) Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF). JACC Heart Fail 11(1):1–14. https://doi.org/10.1016/j.jchf.2022.08.009
doi: 10.1016/j.jchf.2022.08.009
pubmed: 36202739
Mejía-Vilet JM, Ramírez V, Cruz C, Uribe N, Gamba G, Bobadilla NA (2007) Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 293(1):F78-86. https://doi.org/10.1152/ajprenal.00077.2007
doi: 10.1152/ajprenal.00077.2007
pubmed: 17376767
Monrad SU, Killen PD, Anderson MR, Bradke A, Kaplan MJ (2008) The role of aldosterone blockade in murine lupus nephritis. Arthritis Res Ther 10(1):R5. https://doi.org/10.1186/ar2353
doi: 10.1186/ar2353
pubmed: 18197980
pmcid: 2374470
Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ (2008) Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 51(2):199–211. https://doi.org/10.1053/j.ajkd.2007.10.040
doi: 10.1053/j.ajkd.2007.10.040
pubmed: 18215698
Chrysostomou A, Becker G (2001) Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345(12):925–926. https://doi.org/10.1056/NEJM200109203451215
doi: 10.1056/NEJM200109203451215
pubmed: 11565535
Bomback AS, Kshirsagar AV, Klemmer PJ (2009) Renal aspirin: will all patients with chronic kidney disease one day take spironolactone? Nat Clin Pract Nephrol 5(2):74–75. https://doi.org/10.1038/ncpneph1004
doi: 10.1038/ncpneph1004
pubmed: 19029998
Chung EY, Ruospo M, Natale P et al (2020) Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 10(10):CD007004. https://doi.org/10.1002/14651858.CD007004.pub4
doi: 10.1002/14651858.CD007004.pub4
pubmed: 33107592
Currie G, Taylor AH, Fujita T et al (2016) Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol 17(1):127. https://doi.org/10.1186/s12882-016-0337-0
doi: 10.1186/s12882-016-0337-0
pubmed: 27609359
pmcid: 5015203
Hou J, Xiong W, Cao L, Wen X, Li A (2015) Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis. Clin Ther 37(9):2086-2103.e2010. https://doi.org/10.1016/j.clinthera.2015.05.508
doi: 10.1016/j.clinthera.2015.05.508
pubmed: 26254276
Matsumoto Y, Mori Y, Kageyama S et al (2014) Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 63(6):528–536. https://doi.org/10.1016/j.jacc.2013.09.056
doi: 10.1016/j.jacc.2013.09.056
pubmed: 24184249
Charytan DM, Himmelfarb J, Ikizler TA et al (2019) Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int 95(4):973–982. https://doi.org/10.1016/j.kint.2018.08.034
doi: 10.1016/j.kint.2018.08.034
pubmed: 30473139
Hammer F, Malzahn U, Donhauser J et al (2019) A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int 95(4):983–991. https://doi.org/10.1016/j.kint.2018.11.025
doi: 10.1016/j.kint.2018.11.025
pubmed: 30712923
Hasegawa T, Nishiwaki H, Ota E, Levack WM, Noma H (2021) Aldosterone antagonists for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2(2):CD013109. https://doi.org/10.1002/14651858.CD013109.pub2
doi: 10.1002/14651858.CD013109.pub2
pubmed: 33586138
Bärfacker L, Kuhl A, Hillisch A et al (2012) Discovery of BAY 94–8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7(8):1385–1403. https://doi.org/10.1002/cmdc.201200081
doi: 10.1002/cmdc.201200081
pubmed: 22791416
Amazit L, Le Billan F, Kolkhof P et al (2015) Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem 290(36):21876–21889. https://doi.org/10.1074/jbc.M115.657957
doi: 10.1074/jbc.M115.657957
pubmed: 26203193
pmcid: 4571943
Kolkhof P, Delbeck M, Kretschmer A et al (2014) Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64(1):69–78. https://doi.org/10.1097/FJC.0000000000000091
doi: 10.1097/FJC.0000000000000091
pubmed: 24621652
Snelder N, Heinig R, Drenth HJ et al (2020) Population pharmacokinetic and exposure-response analysis of finerenone: insights based on phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease. Clin Pharmacokinet 59(3):359–370. https://doi.org/10.1007/s40262-019-00820-x
doi: 10.1007/s40262-019-00820-x
pubmed: 31583611
Grune J, Beyhoff N, Smeir E et al (2018) Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone’s antifibrotic activity. Hypertension 71(4):599–608. https://doi.org/10.1161/HYPERTENSIONAHA.117.10360
doi: 10.1161/HYPERTENSIONAHA.117.10360
pubmed: 29437893
Barrera-Chimal J, Estrela GR, Lechner SM et al (2018) The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int 93(6):1344–1355. https://doi.org/10.1016/j.kint.2017.12.016
doi: 10.1016/j.kint.2017.12.016
pubmed: 29548765
Lattenist L, Lechner SM, Messaoudi S et al (2017) Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension 69(5):870–878. https://doi.org/10.1161/HYPERTENSIONAHA.116.08526
doi: 10.1161/HYPERTENSIONAHA.116.08526
pubmed: 28320854
González-Blázquez R, Somoza B, Gil-Ortega M et al (2018) Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress. Front Pharmacol 9:1131. https://doi.org/10.3389/fphar.2018.01131
doi: 10.3389/fphar.2018.01131
pubmed: 30356804
pmcid: 6189469
Marzolla V, Feraco A, Limana F, Kolkhof P, Armani A, Caprio M (2022) Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists. J Endocrinol Invest 45(1):215–220. https://doi.org/10.1007/s40618-021-01635-z
doi: 10.1007/s40618-021-01635-z
pubmed: 34272678
Kolkhof P, Hartmann E, Freyberger A et al (2021) Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am J Nephrol 52(8):642–652. https://doi.org/10.1159/000516213
doi: 10.1159/000516213
pubmed: 34111864
Pitt B, Kober L, Ponikowski P et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34(31):2453–2463. https://doi.org/10.1093/eurheartj/eht187
doi: 10.1093/eurheartj/eht187
pubmed: 23713082
pmcid: 3743070
Filippatos G, Anker SD, Böhm M et al (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 37(27):2105–2114. https://doi.org/10.1093/eurheartj/ehw132
doi: 10.1093/eurheartj/ehw132
pubmed: 27130705
pmcid: 4946749
Bakris GL, Agarwal R, Chan JC et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314(9):884–894. https://doi.org/10.1001/jama.2015.10081
doi: 10.1001/jama.2015.10081
pubmed: 26325557
Filippatos G, Anker SD, Pitt B et al (2022) Finerenone and heart failure outcomes by kidney function/albuminuria in chronic kidney disease and diabetes. JACC Heart Fail 10(11):860–870. https://doi.org/10.1016/j.jchf.2022.07.013
doi: 10.1016/j.jchf.2022.07.013
pubmed: 36328655
Filippatos G, Anker SD, Agarwal R et al (2022) Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation 145(6):437–447. https://doi.org/10.1161/CIRCULATIONAHA.121.057983
doi: 10.1161/CIRCULATIONAHA.121.057983
pubmed: 34775784
Filippatos G, Bakris GL, Pitt B et al (2021) Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol 78(2):142–152. https://doi.org/10.1016/j.jacc.2021.04.079
doi: 10.1016/j.jacc.2021.04.079
pubmed: 34015478
Filippatos G, Pitt B, Agarwal R et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail 24(6):996–1005. https://doi.org/10.1002/ejhf.2469
doi: 10.1002/ejhf.2469
pubmed: 35239204
Rossing P, Anker SD, Filippatos G et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care 45(12):2991–2998. https://doi.org/10.2337/dc22-0294
doi: 10.2337/dc22-0294
pubmed: 35972218
pmcid: 9862372
Duggan S (2019) Esaxerenone: first global approval. Drugs 79(4):477–481. https://doi.org/10.1007/s40265-019-01073-5
doi: 10.1007/s40265-019-01073-5
pubmed: 30806972
Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S (2020) Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension 75(1):51–58. https://doi.org/10.1161/HYPERTENSIONAHA.119.13569
doi: 10.1161/HYPERTENSIONAHA.119.13569
pubmed: 31786983
Ito S, Kashihara N, Shikata K et al (2020) Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol 15(12):1715–1727. https://doi.org/10.2215/CJN.06870520
doi: 10.2215/CJN.06870520
pubmed: 33239409
pmcid: 7769030
Wada T, Inagaki M, Yoshinari T et al (2021) Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin Exp Nephrol 25(2):120–130. https://doi.org/10.1007/s10157-020-01963-z
doi: 10.1007/s10157-020-01963-z
pubmed: 32974732
Bamberg K, Johansson U, Edman K et al (2018) Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS One 13(2):e0193380. https://doi.org/10.1371/journal.pone.0193380
doi: 10.1371/journal.pone.0193380
pubmed: 29474466
pmcid: 5825103
Weldon SM, Brown NF (2019) Inhibitors of aldosterone synthase. Vitam Horm 109:211–239. https://doi.org/10.1016/bs.vh.2018.10.002
doi: 10.1016/bs.vh.2018.10.002
pubmed: 30678857
Dogra S, Shah S, Gitzel L et al (2023) Baxdrostat: a novel aldosterone synthase inhibitor for treatment resistant hypertension. Curr Probl Cardiol 48:101918. https://doi.org/10.1016/j.cpcardiol.2023.101918
doi: 10.1016/j.cpcardiol.2023.101918
pubmed: 37399857
Freeman MW, Halvorsen YD, Marshall W et al (2023) Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med 388(5):395–405. https://doi.org/10.1056/NEJMoa2213169
doi: 10.1056/NEJMoa2213169
pubmed: 36342143
Bhatt D (2023) Efficacy and safety of baxdrostat in patients with uncontrolled hypertension - HALO [oral presentation]. Presented at American College of Cardiology Annual Scientific Session (ACC.23/WCC), New Orleans, LA, 4–6 March 2023. Available from acc.org/Latest-in-Cardiology/Clinical-Trials/2023/03/01/23/34/halo. Accessed 19 Sep 2023
Beygui F, Cayla G, Roule V et al (2016) Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial. J Am Coll Cardiol 67(16):1917–1927. https://doi.org/10.1016/j.jacc.2016.02.033
doi: 10.1016/j.jacc.2016.02.033
pubmed: 27102506
Montalescot G, Pitt B, Lopez de Sa E et al (2014) Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J 35(34):2295–2302. https://doi.org/10.1093/eurheartj/ehu164
doi: 10.1093/eurheartj/ehu164
pubmed: 24780614